Health Enhancement Products, Changing Times Vitamins terminate their current distribution agreement

Health Enhancement Products, Inc. (OTC BB: HEPI.OB) and Changing Times Vitamins today announced, they have mutually agreed to terminate their current distribution agreement, in which Changing Times Vitamins had acquired the exclusive rights to distribute ProAlgaZyme (PAZ).

Under terms of the definitive agreement, HEPI retains all marketing and sales rights associated with the Company's proprietary ProAlgaZyme(TM) (PAZ) compound. HEPI will also retain control of all remaining inventory, labels, bottles, promotional materials, as well as customer contact information.

Peter Vitulli, Interim CEO of HEPI, commented, "Since joining the Company just a few short weeks ago, I have quickly recognized the immense potential that exists with our lead bioactive compound, PAZ. As such, I have initiated a series of steps to better position the Company for future growth. The first step is to control every aspect of PAZ's distribution, marketing and sales going forward. This decision is in the best interest of the Company as it allows us the freedom to evaluate multiple strategic options to maximize the true value of PAZ for our shareholders." Mr. Vitulli continued, "We continue to be greatly encouraged by the preliminary findings from Wayne State University and look forward to providing additional results in the coming weeks, along with more detailed information regarding the various opportunities available to the Company going forward."

SOURCE Health Enhancement Products, Inc.

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Single-dose of psilocybin shows long-term relief for depression in cancer patients